KR950031061A - 과반응성 염증 질환 치료용 약제를 제조하기 위한 데옥시스페르구알린의 용도 - Google Patents

과반응성 염증 질환 치료용 약제를 제조하기 위한 데옥시스페르구알린의 용도 Download PDF

Info

Publication number
KR950031061A
KR950031061A KR1019950005896A KR19950005896A KR950031061A KR 950031061 A KR950031061 A KR 950031061A KR 1019950005896 A KR1019950005896 A KR 1019950005896A KR 19950005896 A KR19950005896 A KR 19950005896A KR 950031061 A KR950031061 A KR 950031061A
Authority
KR
South Korea
Prior art keywords
use according
disease
medicament
prepared
deoxyspergualline
Prior art date
Application number
KR1019950005896A
Other languages
English (en)
Other versions
KR100338579B1 (ko
Inventor
린드너 위르겐
디크나이테 게르하르트
쇼를레머 한스-울리히
보슬레트 클라우스
Original Assignee
슈타인, 라우페
베링베르케 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4409804A external-priority patent/DE4409804A1/de
Priority claimed from DE19944415553 external-priority patent/DE4415553A1/de
Application filed by 슈타인, 라우페, 베링베르케 아크티엔게젤샤프트 filed Critical 슈타인, 라우페
Publication of KR950031061A publication Critical patent/KR950031061A/ko
Application granted granted Critical
Publication of KR100338579B1 publication Critical patent/KR100338579B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

본 발명은 사람 및 동물의 과반응성 염증 질환 치료용 및 예방용 약제를 제조하기 위한 데옥시스페르구알린의 용도에 관한 것이다.

Description

과반응성 염증 질환 치료용 약제를 제조하기 위한 데옥시스페르구알린의 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 데옥시스페르구알린(DSG)을 투여량-의존 방법으로 투여함으로써 경동맥의 동맥경화성 병변에 의한 동맥내막의 신생(the formation of neointima)이 현저히 억제됨을 나타낸다.

Claims (9)

  1. 과반응성 염증 질환 치료용 및 예방용 약제를 제조하기 위한 데옥시스페르구알린의 용도.
  2. 제1항에 있어서, 활성 입체이성체를 사용하는 용도.
  3. 제1항에 있어서, 질환이 만성 염증 장 질환, 과반응성 장해성 기도 질환, 만성 염증 혈관 질환 또는 뇌의 만성 감염 질환인 용도.
  4. 제1항에 있어서, 질환이 궤양성대장염, 천식, 동맥경화, 췌장염, 패혈증 또는 알쯔하이머 질환인 용도.
  5. 제1항에 있어서, 추가의 활성 화합물과 배합물이 제조되는 용도.
  6. 제1항에 있어서, 메트로니다졸과의 배합물이 제조되는 용도.
  7. 제1항에 있어서, 데옥시스페르구알린을 함유하는 약제가 0.1 내지 100㎎/㎏용량으로 제조되는 용도.
  8. 제1항에 있어서, 약제가 경구, 정맥내, 피하, 피부내, 복막내,포막내, 눈내, 눈, 볼, 비강, 경피, 피부, 국소, 흡입, 근육내 또는 직장 투여용으로 제조되는 용도.
  9. 제1항에 있어서, 약제가 정맥내 또는 경구 투여용으로 제조되는 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950005896A 1994-03-22 1995-03-21 데옥시스페르구알린을함유하는과반응성염증성질환치료용약제학적조성물 KR100338579B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE4409804A DE4409804A1 (de) 1994-03-22 1994-03-22 Verwendung von Deoxyspergualin zur Herstellung eines Arzneimittels zur Behandlung von entzündlich-hyperreaktiven Erkrankungen
DEP4409804.9 1994-03-22
DEP4415553.0 1994-05-03
DE19944415553 DE4415553A1 (de) 1994-05-03 1994-05-03 Verwendung von Deoxyspergualin zur Herstellung eines Arzneimittels zur Behandlung von entzündlich-hyperreaktiven Erkrankungen

Publications (2)

Publication Number Publication Date
KR950031061A true KR950031061A (ko) 1995-12-18
KR100338579B1 KR100338579B1 (ko) 2002-11-23

Family

ID=25934947

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950005896A KR100338579B1 (ko) 1994-03-22 1995-03-21 데옥시스페르구알린을함유하는과반응성염증성질환치료용약제학적조성물

Country Status (11)

Country Link
US (1) US5849799A (ko)
EP (1) EP0673646B1 (ko)
JP (2) JP3483646B2 (ko)
KR (1) KR100338579B1 (ko)
AT (1) ATE173921T1 (ko)
AU (1) AU712361B2 (ko)
CA (1) CA2145211C (ko)
DE (1) DE59504374D1 (ko)
DK (1) DK0673646T3 (ko)
ES (1) ES2124926T3 (ko)
NZ (1) NZ270749A (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294581B1 (en) * 1998-05-15 2001-09-25 Takara Shuzo Co., Ltd. Inhibition of IgA production
DE19923961A1 (de) * 1999-05-25 2000-11-30 Euro Nippon Kayaku Gmbh Verwendung von 15-Deoxyspergualin zur Behandlung von hyperreaktiven entzündlichen Erkrankungen und Autoimmunerkrankungen
US20030166732A1 (en) * 2002-02-27 2003-09-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity
JP2006117569A (ja) * 2004-10-20 2006-05-11 Juntendo ステロイド依存性あるいはステロイド抵抗性潰瘍性大腸炎治療薬

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851446A (en) * 1984-11-13 1989-07-25 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Immunosuppressing method
JPS61134312A (ja) * 1984-12-06 1986-06-21 Microbial Chem Res Found 移植免疫抑制剤並びに抗アレルギ−剤
DE3626306A1 (de) * 1986-08-02 1988-02-11 Behringwerke Ag Verwendung von 15-deoxyspergualin als arzneimittel
GB9126870D0 (en) * 1991-12-18 1992-02-19 Fujisawa Pharmaceutical Co Novel compound
US5238689A (en) * 1992-01-07 1993-08-24 Procept, Inc. Use of ruthenium red as immunosuppressive agents
GB9203265D0 (en) * 1992-02-15 1992-04-01 Fisons Plc Pharmaceutically active compound
DE4329503A1 (de) * 1993-09-01 1995-03-02 Galenik Labor Freiburg Gmbh Pharmazeutische Präparate zur gezielten Behandlung von Morbus Crohn und Colitis Ulcerosa

Also Published As

Publication number Publication date
JP2003286160A (ja) 2003-10-07
KR100338579B1 (ko) 2002-11-23
ES2124926T3 (es) 1999-02-16
CA2145211A1 (en) 1995-09-23
EP0673646A3 (de) 1995-12-27
CA2145211C (en) 2002-10-15
EP0673646B1 (de) 1998-12-02
ATE173921T1 (de) 1998-12-15
EP0673646A2 (de) 1995-09-27
JPH0840887A (ja) 1996-02-13
US5849799A (en) 1998-12-15
AU1494395A (en) 1995-09-28
DE59504374D1 (de) 1999-01-14
NZ270749A (en) 1997-03-24
JP3483646B2 (ja) 2004-01-06
DK0673646T3 (da) 1999-08-16
AU712361B2 (en) 1999-11-04

Similar Documents

Publication Publication Date Title
PL307339A1 (en) Terephandin metabolites and their optically pure isomers for treating allergic disorders
DE69232462D1 (de) Formoterol und budesonide enthaltende zusammensetzung
DE69418601D1 (de) Guanidinderivate mit therapeutischer wirkung
KR960703009A (ko) 중추유래의 수면성 무호흡증 및 호흡곤란증의 치료를 위한 모다피닐의 사용
TW200607510A (en) Use of optically pure (s.s)-reboxetine in the manufacture of a medicament for the treatment or prevention of fibromyalgia or another somatoform disorder
HUP0401192A2 (hu) Fényérzékenyítő szer alkalmazása sebek kezelésére adható gyógyászati készítmény előállítására
AU2003263878A1 (en) Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventive agents
GB2285219B (en) Use of norastemizole for the treatment of allergic disorders
DE69627160D1 (de) Pharmazeutische zusammensetzung enthaltend 3-(2,2,2-trimethylhydrazinium)proprionat und gamma-butyrobetain für die behandlung von herz-gefäss-erkrankungen
KR950031061A (ko) 과반응성 염증 질환 치료용 약제를 제조하기 위한 데옥시스페르구알린의 용도
CA2474703A1 (en) Therapeutic agent of glaucoma comprising bunazosin and prostaglandins
KR950701518A (ko) 알쯔하이머 질환의 치료에 있어서 (E)-2-(p-플로오로펜에틸)-3-플루오로알릴아민의 용도(Use of (E)-2-(p-fluorophenethyl)-3-fluoroallylamine in the treatmet of Alzheimer's disease)
CROMWELL et al. HYPERSENSITIVITY TO INTRAVENOUS MORPHINE SULFATE: Case Report
TH16073A (th) วิธีการใช้ เฮสเพอเรทิน เพื่อการควบคุมไขผิวหนังและการบำบัดสิว

Legal Events

Date Code Title Description
N231 Notification of change of applicant
A201 Request for examination
N231 Notification of change of applicant
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120312

Year of fee payment: 11

FPAY Annual fee payment

Payment date: 20130307

Year of fee payment: 12

LAPS Lapse due to unpaid annual fee